Radiotherapy after prostatectomy in high‑risk prostate cancer

Roviello, Giandomenico; Villari, Donata; Nesi, Gabriella; Detti, Beatrice

doi:10.1007/s12094-020-02342-6

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two major categories of radiotherapy for PC are external beam radiotherapy (EBRT) and brachytherapy (BT), both of which have improved with the use of high-quality multimodal imaging and robotic assistance (18,19). A large number of randomized controlled clinical trials have assessed the efficacy and safety of radiotherapy (20,21). Ra-223 is a first-in-class, a-particleemitting, radioactive agent used as the first-line therapy for PC (FDA approved in 2013), which has provided an additional treatment option for patients with CRPC and symptomatic bone metastases in the absence of visceral metastases (22).…”

Section: Radiotherapymentioning

confidence: 99%

Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

et al. 2021

View full text Add to dashboard Cite

The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.

show abstract